

# **Global Dengue Vaccine Market: By Product Type (CYD-TDV (Dengvaxia), DENVax, TetraVax-DV, and Others), By Vaccine Type (Live Attenuated Vaccine, Killed Vaccine, and Others), By End Users (Hospitals, Clinics, Government Institutes, and Non-Governmental Organizations (NGOs)) and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 and Forecast 2017-2023**

<https://marketpublishers.com/r/G5B3A6B0E93EN.html>

Date: September 2017

Pages: 193

Price: US\$ 4,400.00 (Single User License)

ID: G5B3A6B0E93EN

## **Abstracts**

### **Global Dengue Vaccine Market Report Description:**

Dengue vaccine market report gives a comprehensive outlook of dengue vaccine market across the globe with special emphasis on key regions such as Asia-Pacific, Latin America, and Middle East & Africa (MEA) North America, and Europe. This report on dengue vaccine market gives historical, current, and future market sizes (US\$ Mn) of product types, vaccine type, end users, and geographic regions. This report studies dengue vaccine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, dengue vaccine market report covers newer product introductions and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed dengue vaccine market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the dengue vaccine market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of dengue vaccine.

## Dengue Vaccine Market:

The dengue vaccine market estimated to be valued at US\$ 235 Mn in 2017 and poised to grow at CAGR 27.7%. Market for dengue vaccines projected to reach US\$ 1020 Mn by 2023 due to newer product launches and dearth of treatment options.

## Increase in Burden of Dengue Fever in Tropical and Subtropical Regions

Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by *Aedes aegypti* mosquito. Dengue fever is epidemic in several countries of Asia-Pacific and Latin America region. The growing global epidemic of dengue in aforementioned regions is expected to create demand for the dengue vaccine over the forecast period. Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for dengue vaccine over the forecast period. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programs to prevent the dengue epidemics. According to WHO estimates, there are around 50 Mn dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.

## Promising Vaccine Pipeline

Currently dengvaxia is the only vaccine available for dengue prevention in the market. Dengvaxia (CYD-TDV) is a recombinant tetravalent vaccine administered in three doses in series of 0/3/6 month schedule. However, there are around five dengue vaccine candidates are under development, which are showing positive results in different clinical trial phases. Moreover, vaccine like DENVax from Takeda Pharmaceutical Company Limited is showing better clinical benefits in all age groups and have convenient dosing pattern i.e. two doses (three months apart). Developing clinically efficacious vaccines in flexible dosing regimens expected to fuel the dengue vaccine market revenue growth over the forecast period.

## Asia-Pacific Region Expected To Emerge As Leading Market for Dengue Vaccine

Asia-Pacific region expected to lead the global dengue vaccine market owing to widespread prevalence and incidence of dengue fever and large population, who are at dengue fever risk. Latin America expected to register highest market growth among all regions owing to early adoption of vaccine in government immunization programs.

## COMPETITION ASSESSMENT

Key players profiles in the global dengue vaccine market include:

Sanofi (France)

Takeda Pharmaceutical Company Limited (Japan)

Instituto Butantan (Brazil)

Vabiotech (Vietnam)

Panacea Biotech (India)

Biological E (India)

GlaxoSmithKline plc (U.K)

Merck & Co. Inc. (U.S.)

Market players are focusing on developing live and killed vaccines with improved safety and efficacy to garner larger revenue share in global dengue vaccine market.

## KEY FINDINGS OF THE REPORT:

Global dengue vaccine market expanding at 27.7% CAGR over 2017 to 2023 to reach market value of US\$ 1020 Mn by 2023

Based on product type CYD-TDV expected to hold larger revenue share in short term owing to first mover advantage

Government institutes are expected to emerge as prime buyers for dengue vaccine across the globe owing to incorporation of dengue vaccine in immunization programs

Players focusing on live and killed vaccines with improved safety and efficacy to garner larger revenue share in global dengue vaccine market.

## KEY FEATURES OF THE REPORT:

The report provides granular level information about the market size, regional market share, historic market (2016) and forecast (2017-2023)

The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies

The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

The report tracks recent innovations, key developments and startup's details that are actively working in the market

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

## DETAILED SEGMENTATION

### By Product Type

CYD-TDV (Dengvaxia)

DENVax

TetraVax-DV

Others

### By Vaccine Type

Live Attenuated Vaccine

Killed Vaccine

Others

## By End Users

Hospitals

Clinics

Government Institutes

Non-Governmental Organization (NGOs)

## Geography

North America

U.S

Canada

Europe

Germany

France

U.K

Italy

Spain

Russia

Poland

Rest of Europe

Asia-Pacific

Japan

China

India

Australia & New Zealand

ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)

South Korea

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Argentina

Venezuela

Rest of Latin America

Middle East and Africa (MEA)

Gulf Cooperation Council (GCC) Countries

Israel

South Africa

Rest of MEA

## Contents

### **1. RESEARCH METHODOLOGY**

- 1.1. Secondary and Primary research
  - 1.1.1. Secondary Sources
  - 1.1.2. Primary Sources
- 1.2. Market Revenue Estimation Methodology
- 1.3. Key Assumptions
- 1.4. Acronyms

### **2. SCOPE OF STUDY**

- 2.1. Market Definition
- 2.2. Objective of the Research
- 2.3. Regions covered in the study

### **3. EXECUTIVE SUMMARY**

### **4. GLOBAL DENGUE VACCINE MARKET DYNAMICS**

- 4.1. Drivers
  - 4.1.1. Economic Drivers
  - 4.1.2. Demand Side Drivers
  - 4.1.3. Supply Side Drivers
- 4.2. Restraints
- 4.3. Opportunities/Unmet Needs of the Market
- 4.4. Trends

### **5. UNIQUE FEATURES OF THE REPORT**

- 5.1. Competition analysis
- 5.2. Regulatory landscape
- 5.3. PESTLE analysis
- 5.4. Porter's analysis

### **6. GLOBAL DENGUE VACCINE MARKET ANALYSIS, BY PRODUCT TYPE, 2016 AND FORECAST, 2017 - 2023**



### 6.1. CYD-TDP (Dengvaxia)

6.1.1. Market Analysis, 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 6.2. DENVax

6.2.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 6.3. TetraVax-DV

6.3.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 6.4. Others

6.4.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

## **7. GLOBAL DENGUE VACCINE MARKET ANALYSIS, BY VACCINE TYPE, 2016 AND FORECAST, 2017 - 2023**

### 7.1. Live Attenuated Vaccine

7.1.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 7.2. Killed Vaccines

7.2.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 7.3. Others

7.3.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

## **8. GLOBAL DENGUE VACCINE MARKET FORECAST, BY END USERS ANALYSIS, 2016 AND FORECAST, 2017 - 2023**

### 8.1. Hospitals

8.1.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 8.2. Clinics

8.2.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 8.3. Government Institutes

8.3.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### 8.4. Non-Governmental Organization (NGOs)

8.4.1. Market Analysis, 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

## **9. DENGUE VACCINE MARKET ANALYSIS, BY REGION, 2016 AND FORECAST, 2017 - 2023**

9.1. North America Dengue Vaccine Market Analysis, 2016 and Forecast, 2017 - 2023

9.1.1. Product Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

9.1.1.1. CYD-TDV (Dengvaxia)

9.1.1.2. DENVax

9.1.1.3. TetraVax-DV

9.1.1.4. Others

9.1.2. Vaccine Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

9.1.2.1. Live Attenuated Vaccine

9.1.2.2. Killed Vaccine

9.1.2.3. Others

9.1.3. End User Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

9.1.3.1. Hospital

9.1.3.2. Clinics

9.1.3.3. Government Institutes

9.1.3.4. Non-Governmental Organization (NGOs)

9.1.4. Country Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.2. Europe Dengue Vaccine Market Analysis, 2016 and Forecast, 2017 - 2023

9.2.1. Drugs Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

9.2.1.1. CYD-TDV (Dengvaxia)

9.2.1.2. DENVax

9.2.1.3. TetraVax-DV

9.2.1.4. Others

9.2.2. Vaccine Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

9.2.2.1. Live Attenuated Vaccine

9.2.2.2. Killed Vaccine

#### 9.2.2.3. Others

9.2.3. End User Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.2.3.1. Hospital

##### 9.2.3.2. Clinics

##### 9.2.3.3. Government Institutes

##### 9.2.3.4. Non-Governmental Organization (NGOs)

9.2.4. Country Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.2.4.1. U.K

##### 9.2.4.2. Germany

##### 9.2.4.3. France

##### 9.2.4.4. Italy

##### 9.2.4.5. Spain

##### 9.2.4.6. Russia

##### 9.2.4.7. Poland 9.2.4.8. Rest of Europe

9.3. Asia-Pacific Dengue Vaccine Market Analysis, 2016 and Forecast, 2017 - 2023

9.3.1. Product Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.3.1.1. CYD-TDV (Dengvaxia)

##### 9.3.1.2. DENVax

##### 9.3.1.3. TetraVax-DV

##### 9.3.1.4. Others

9.3.2. Vaccine Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.3.2.1. Live Attenuated Vaccine

##### 9.3.2.2. Killed Vaccine

##### 9.3.2.3. Others

9.3.3. End User Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.3.3.1. Hospital

##### 9.3.3.2. Clinics

##### 9.3.3.3. Government Institutes

##### 9.3.3.4. Non-Governmental Organization (NGOs)

9.3.4. Country Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.3.4.1. Japan

##### 9.3.4.2. China

##### 9.3.4.3. India

#### 9.3.4.4. ASEAN

#### 9.3.4.5. Australia & New Zealand 9.3.4.6. Rest of Asia-Pacific

### 9.4. Latin America Dengue Vaccine Market Analysis, 2016 and Forecast, 2017 - 2023

#### 9.4.1. Product Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.4.1.1. CYD-TDV (Dengvaxia)

##### 9.4.1.2. DENVax

##### 9.4.1.3. TetraVax-DV

##### 9.4.1.4. Others

#### 9.4.2. Dengue Vaccine Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.4.2.1. Live Attenuated Vaccine

##### 9.4.2.2. Killed Vaccine

##### 9.4.2.3. Others

#### 9.4.3. End User Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.4.3.1. Hospital

##### 9.4.3.2. Clinics

##### 9.4.3.3. Government Institutes

##### 9.4.3.4. Non-Governmental Organization (NGOs)

#### 9.4.4. Country Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.4.4.1. Brazil

##### 9.4.4.2. Mexico

##### 9.4.4.3. Argentina

##### 9.4.4.4. Venezuela

##### 9.4.4.5. Rest of Latin America

### 9.5. Middle East & Africa (MEA) Dengue Vaccine Market Analysis, 2016 and Forecast, 2017 - 2023

#### 9.5.1. Product Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.5.1.1. CYD-TDV (Dengvaxia)

##### 9.5.1.2. DENVax

##### 9.5.1.3. TetraVax-DV

##### 9.5.1.4. Others

#### 9.5.2. Dengue Vaccine Type Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.5.2.1. Live Attenuated Vaccine

##### 9.5.2.2. Killed Vaccine

#### 9.5.2.3. Others

9.5.3. End User Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.5.3.1. Hospital

##### 9.5.3.2. Clinics

##### 9.5.3.3. Government Institutes

##### 9.5.3.4. Non-Governmental Organization (NGOs)

9.5.4. Country Analysis ( 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

##### 9.5.4.1. Gulf Cooperation Council (GCC) Countries

##### 9.5.4.2. Israel

##### 9.5.4.3. South Africa

##### 9.5.4.4. Rest of MEA

## 10. COMPETITION LANDSCAPE

10.1. Strategic Dashboard of Top Market Players

10.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

##### 10.2.1. Sanofi (France)

##### 10.2.2. Takeda Pharmaceutical Company Limited (Japan)

##### 10.2.3. Insitituto Butantan (Brazil)

##### 10.2.4. Vabiotech (Vietnam)

##### 10.2.5. Panacea Biotech (India)

##### 10.2.6. Biological E (India)

##### 10.2.7. GlaxoSmithKline plc (U.K)

##### 10.2.8. Merck & Co. Inc. (U.S.)

## I would like to order

Product name: Global Dengue Vaccine Market: By Product Type (CYD-TDV (Dengvaxia), DENVax, TetraVax-DV, and Others), By Vaccine Type (Live Attenuated Vaccine, Killed Vaccine, and Others), By End Users (Hospitals, Clinics, Government Institutes, and Non-Governmental Organizations (NGOs)) and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G5B3A6B0E93EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5B3A6B0E93EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970